Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

BioMarin Pharmaceutical Inc. (BMRN) Surges But Is It A Good Stock To Buy Now?

According to our database, Julian Baker and Felix Baker’s Baker Bros. Advisors had the largest position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), worth close to $523.5 million, corresponding to 4.4% of its total 13F portfolio. The second largest stake is held by John Griffin of Blue Ridge Capital, with a $277.9 million position. Blue Ridge Capital has 3.2% of its 13F portfolio invested in the stock. Remaining members of the smart money that are bullish contain William Leland Edwards’s Palo Alto Investors, Paul Orlin and Alex Porter’s Amici Capital and Jerome Pfund and Michael Sjostrom’s Sectoral Asset Management.

Due to the fact that BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has faced declining sentiment from the entirety of the hedge funds we track, logic holds that there is a sect of hedge funds that decided to sell off their full holdings in first quarter. It’s worth mentioning that Jason Karp’s Tourbillon Capital Partners dumped the biggest stake of the “upper crust” of funds followed by Insider Monkey, totaling about $37.5 million in stock. Nick Niell’s fund, Arrowgrass Capital Partners, also sold off its holdings, about $25.5 million worth.

Biotech stocks are currently richly valued. Since hedge fund sentiment is neutral andinsider sentiment is slightly negative, even though news of the company’s BMN 111 drug’s positive phase 2 study has come out, we will pass on recommending a long position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.